Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other analysts have also recently issued research reports about the company. Royal Bank of Canada lowered their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, January 13th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $40.00 to $15.00 in a report on Monday, January 13th. Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.56.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $5.93 on Friday. The company has a market capitalization of $274.14 million, a price-to-earnings ratio of -2.08 and a beta of 2.81. 4D Molecular Therapeutics has a fifty-two week low of $4.43 and a fifty-two week high of $36.25. The stock has a fifty day moving average of $5.97 and a 200-day moving average of $10.05.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers increased its stake in 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after purchasing an additional 3,675 shares during the period. Peapod Lane Capital LLC purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $806,000. Marquette Asset Management LLC purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $116,000. Barclays PLC increased its stake in 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock worth $1,241,000 after purchasing an additional 67,202 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its stake in 4D Molecular Therapeutics by 81.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock worth $265,000 after purchasing an additional 11,002 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.